Yap, T. A., Gulley, J. L., Sharma, M. R., LoRusso, P., Barnes, C. N., Decaris, M., Amaya, J. C. A. (2026). Cohort expansion of a phase I study of PLN-101095, a first-in-class dual α v β 8 /α v β 1 integrin inhibitor, in combination with pembrolizumab in patients with advanced solid tumors refractory to immune checkpoint inhibitors (ICI).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.tps2690